--- title: "Tectonic Therapeutic IncQ) expected to post a loss of $1.03 a share - Earnings Preview" description: "Tectonic Therapeutic IncQ) is projected to report a loss of $1.03 per share for the quarter ending September 30, 2025, with no change in revenue. Analysts maintain a \"buy\" rating, with a median 12-mon" type: "news" locale: "en" url: "https://longbridge.com/en/news/252216093.md" published_at: "2025-08-08T11:17:06.000Z" --- # Tectonic Therapeutic IncQ) expected to post a loss of $1.03 a share - Earnings Preview > Tectonic Therapeutic IncQ) is projected to report a loss of $1.03 per share for the quarter ending September 30, 2025, with no change in revenue. Analysts maintain a "buy" rating, with a median 12-month price target of $80.50, significantly above its last closing price of $21.92. Recent earnings estimates have increased by 3.3% over the past three months. Previous quarterly performances show mixed results, with several misses and beats in earnings expectations. - Tectonic Therapeutic Inc (TECX.OQ) (TECX.O) is expected to show no change in quarterly revenue when it reports results on August 12 (estimated) for the period ending September 30 2025 - ​LSEG’s mean analyst estimate for Tectonic Therapeutic Inc is for a loss of $1.03 per share. - The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 8 “strong buy” or “buy,” no “hold” and no “sell” or “strong sell.” - The mean earnings estimate of analysts had risen by about 3.3% in the last three months. ​ - Wall Street’s median 12-month price target for Tectonic Therapeutic Inc is $80.50, about 72.8% above its last closing price of $21.92 Previous quarterly performance (using preferred earnings measure in US dollars). ​ ### QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI ### ENDING ARTESTIMAT ESTIMATE MET, SE % ### E® MISSED Jun. 30 2025 -0.96 -0.98 -1.07 Missed -9 Mar. 31 2025 -1.09 -1.09 -0.93 Beat 14.9 Dec. 31 2024 -1.39 -0.84 Beat 39.4​ Sep. 30 2024 -0.82 -0.82 -1.20 Missed -45.5 ​​Jun. -1.40 -1.50 -4.34 Missed -189.3 30 2024 Mar. 31 2024 -4.32 -4.32 -1.80 Beat 58.3​ Dec. 31 2023 -4.95 -4.04 -2.40 Beat 40.6 Sep. 30 2023 -3.34 -3.40 -5.28 Missed -55.3 This summary was machine generated August 8 at 11:17 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) ### Related Stocks - [TECX.US - Tectonic Therapeutic](https://longbridge.com/en/quote/TECX.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Tectonic Metals Upsizes Financing To $80 Million | Tectonic Metals Inc :TECTONIC METALS UPSIZES FINANCING TO $80 MILLIONTECTONIC METALS INC - OFFERING CONSISTS OF 37,210,0 | [Link](https://longbridge.com/en/news/275627549.md) | | Insider Confidence Surges as Tectonic Therapeutic’s CEO Boosts Her Stake | Tectonic Therapeutic's CEO, Alise Reicin, has increased her stake by purchasing 2,500 shares for $52,750, indicating str | [Link](https://longbridge.com/en/news/275841122.md) | | Tectonic Therapeutic CFO Daniel Lochner Reports Acquisition of Common Shares | Tectonic Therapeutic Inc.'s CFO, Daniel Lochner, has reported the acquisition of common shares of the company. The full | [Link](https://longbridge.com/en/news/275669068.md) | | Tectonic Therapeutic Hosts Virtual KOL Event Showcasing TX2100 for Hereditary Hemorrhagic Telangiectasia | Tectonic Therapeutic Inc. (NASDAQ: TECX) will host a virtual KOL event on TX2100, a new treatment for Hereditary Hemorrh | [Link](https://longbridge.com/en/news/275655792.md) | | CICC Reaffirms Their Buy Rating on NIO Inc. Class A (9866) | CICC analyst maintained a Buy rating on NIO Inc. Class A yesterday and set a price target of HK$50.00.Valentine's Day Sa | [Link](https://longbridge.com/en/news/275967598.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.